By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
AbbVie's transition from Humira to Skyrizi and Rinvoq has delivered strong returns, but the upcoming patent cliffs for these drugs pose a significant risk. The market is pricing in limited upside, and the company's obesity pipeline remains unproven. Despite this, AbbVie's cash flow supports its dividend and potential disciplined capital allocation.
Risk: The 2028-2033 patent cliff for Skyrizi and Rinvoq, which could lead to a significant revenue decline and dividend coverage issues if the obesity pipeline fails to deliver.
Opportunity: The potential of AbbVie's obesity pipeline, particularly ABBV-295, to provide a 'third act' and extend the company's growth beyond the patent cliff.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
- ABBV turned $1,000 into $5,000 over 10 years, a 400% return, while its quarterly dividend tripled from $0.57 to $1.73.
- ABBV beat SPY by 139 percentage points over a decade, though defensive pharma lagged the broader market rally over the past year.
- Skyrizi and Rinvoq's combined run rate already surpasses Humira's $21B peak, but a patent cliff threatens both drugs between 2028 and 2033.
- The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbbVie wasn't one of them. Get them here FREE.
Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world's best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, down 38.6% year over year, from a peak around $21 billion annually.
The pivot worked. Skyrizi pulled in $4.483 billion in Q1 2026 (up 30.9%) and Rinvoq added $2.119 billion (up 23.3%). The $63 billion Allergan deal in 2020 brought Botox, Juvederm, and a neuroscience franchise that grew 26% last quarter. Full-year 2025 revenue hit $61.16 billion, and management raised 2026 adjusted EPS guidance to $14.08 to $14.28.
1-Year Return
- Initial Investment:$1,000 - Current Value:$1,189.70 - Total Return:18.97% - S&P 500 (same period):$1,281.50 (28.15%)
5-Year Return
- Initial Investment:$1,000 - Current Value:$2,317.40 - Total Return:131.74% - Annualized Return:roughly 18% - S&P 500 (same period):$1,813.80 (81.38%)
10-Year Return
The analyst who called NVIDIA in 2010 just named his top 10 stocks and AbbVie wasn't one of them. Get them here FREE.
- Initial Investment:$1,000 - Current Value:$5,006.40 - Total Return:400.64% - Annualized Return:roughly 17% - S&P 500 (same period):$3,612.20 (261.22%)
The 10-year number is the headline. AbbVie crushed the index over the long haul while paying out a rising dividend the whole time (the quarterly payout went from $0.57 in 2016 to $1.73 today, and that's before reinvestment). Holding through 2023, when Humira fears peaked, was the hard part. The 1-year lag versus the S&P reflects a broader market rally that left defensive pharma behind.
I'd put $1,000 into AbbVie today if I wanted income plus a credible growth engine, and I believed Skyrizi and Rinvoq can carry the franchise until the next wave of pipeline assets, including the non-incretin obesity program ABBV-295, matures. The combined Skyrizi-Rinvoq run rate already exceeds Humira's peak, and the 3.1% dividend yield with forward P/E near 15 gives me a margin of safety.
Four leading AI models discuss this article
"ABBV's decade-long outperformance was driven by M&A and dividends, not underlying business momentum, and the next 5 years hinge entirely on two drugs facing a hard patent cliff by 2033."
The 10-year return narrative is misleading: it's almost entirely dividend compounding plus Allergan's 2020 acquisition, not organic growth. Strip those out and ABBV's stock price barely kept pace with inflation. The real story is the patent cliff execution — Skyrizi and Rinvoq are genuinely performing, but the article underplays the 2028-2033 cliff risk for both drugs. ABBV-295 obesity program is speculative; obesity drugs face brutal competition (Novo, Eli Lilly). The 1-year underperformance versus SPY (18.97% vs 28.15%) signals the market is pricing in limited upside. At 15x forward P/E on $14.08-$14.28 EPS guidance, valuation is fair, not cheap.
If Skyrizi or Rinvoq face unexpected efficacy/safety issues, or if obesity competition commoditizes pricing faster than expected, ABBV has no third act — the pipeline is thin beyond 2030 and the dividend becomes unsustainable.
"The 2028-2033 patent cliffs on Skyrizi and Rinvoq create a high-probability revenue cliff that the article's bull case underweights."
AbbVie's successful shift from Humira to Skyrizi and Rinvoq has delivered 400% returns over ten years with a rising dividend, but the 2028-2033 patent cliffs for those assets create a structural risk that mirrors the 2023 Humira collapse. The Allergan acquisition added Botox stability, yet the non-incretin obesity program remains early and unproven against entrenched GLP-1 competitors. One-year underperformance versus the S&P already signals that defensive pharma faces valuation pressure when growth slows. Forward P/E near 15 embeds assumptions of sustained double-digit expansion that the timeline does not guarantee.
Skyrizi plus Rinvoq already exceed Humira's prior peak run rate, and management's raised 2026 EPS guidance plus the 3.1% yield could support multiple expansion if pipeline assets like ABBV-295 advance without major delays.
"AbbVie’s current valuation leaves little room for error as it approaches a secondary, more complex patent cliff cycle in the late 2020s."
AbbVie’s successful transition from a Humira-dependent firm to a diversified powerhouse is impressive, but the market is currently pricing for perfection. While Skyrizi and Rinvoq have successfully backfilled the revenue hole, the valuation at a ~15x forward P/E (price-to-earnings ratio) is no longer the bargain it was during the 2023 patent cliff panic. The real risk is the 'patent cliff' looming between 2028 and 2033; investors are essentially paying for growth that is already heavily discounted by future legal and competitive pressures. Unless their non-incretin obesity pipeline, specifically ABBV-295, delivers clinical superiority, AbbVie risks becoming a yield trap rather than a growth compounder.
If AbbVie’s immunology franchise maintains its current momentum and the obesity pipeline shows even moderate success, the 3.1% dividend yield provides a floor that makes the stock a superior risk-adjusted play compared to high-multiple tech growth names.
"AbbVie’s valuation hinges on Skyrizi and Rinvoq delivering sustained mid-to-high single-digit growth to offset Humira declines and support a mid-teens multiple."
AbbVie has pivoted from Humira’s cash flow to a two-drug growth engine, with Allergan assets providing diversification. The 10-year 400% gain and rising dividend highlight durability, and a forward P/E near 15 with a ~3% yield suggests a defensively biased setup. But the article omits two big caveats: biosimilar pressure and safety/regulatory risk could cap Skyrizi/Rinvoq growth long before new pipelines mature, and ABBV-295 remains unproven. If growth slows or margins compress, the stock’s multiple could retract in a rate shock, making today’s price look less compelling despite the dividend cushion.
The hard truth is that Skyrizi and Rinvoq may not sustain Humira-level growth long enough to support a 15x forward multiple, and biosimilar competition could accelerate revenue/margin declines sooner than expected.
"The cliff timeline creates a 5-6 year window for pipeline optionality that the panel is underweighting relative to the binary downside scenario."
Everyone's anchored on the 2028-2033 cliff as binary risk, but nobody's quantified the runway. Skyrizi/Rinvoq combined hit ~$10B run rate by 2027—that's 5-6 years of peak cash generation before erosion. At that scale, ABBV can fund pipeline failures and still maintain the dividend. The real question isn't whether the cliff exists; it's whether management has time to land a third act. ABBV-295 obesity upside is being dismissed too quickly given Allergan's dermatology distribution advantage.
"Development timelines make Claude's runway too optimistic for a viable third act."
Claude's 5-6 year cash runway from a $10B Skyrizi/Rinvoq run rate overlooks typical Phase 3-to-approval timelines for ABBV-295, which often stretch beyond 2028 even with Allergan infrastructure. If obesity trials encounter dosing or efficacy hurdles common in non-incretin candidates, that window closes before any offsetting revenue materializes. Dividend coverage then depends entirely on extending the existing franchise rather than a genuine third act.
"AbbVie's reliance on future M&A to bridge the 2028 revenue gap creates significant risk of capital destruction."
Claude, you’re missing the capital allocation trap. Relying on Skyrizi and Rinvoq to fund a 'third act' ignores that AbbVie’s R&D productivity has historically been mediocre compared to peers. They are essentially a cash-flow-to-dividend machine now, not a growth engine. If the obesity program fails, management will likely resort to desperate, overpriced M&A to plug the 2028 revenue hole, which would destroy shareholder value faster than any patent cliff.
"ABBV can weather obesity risk with capital discipline and optionality, reducing the need for costly M&A."
Gemini's 'capital allocation trap' assumes obesity failure triggers expensive M&A; but ABBV's cash flow already supports disciplined buybacks and smaller collaborations that avoid overpaying. Even if ABBV-295 stalls, a $10B Skyrizi/Rinvoq run rate by 2027 and dividend coverage keep the balance sheet intact. The market underestimates optionality from Botox and manufacturing synergies, which cushions downside beyond the patent cliff significantly.
AbbVie's transition from Humira to Skyrizi and Rinvoq has delivered strong returns, but the upcoming patent cliffs for these drugs pose a significant risk. The market is pricing in limited upside, and the company's obesity pipeline remains unproven. Despite this, AbbVie's cash flow supports its dividend and potential disciplined capital allocation.
The potential of AbbVie's obesity pipeline, particularly ABBV-295, to provide a 'third act' and extend the company's growth beyond the patent cliff.
The 2028-2033 patent cliff for Skyrizi and Rinvoq, which could lead to a significant revenue decline and dividend coverage issues if the obesity pipeline fails to deliver.